Cardiotoxicity of Immune Checkpoint Inhibitors with Anthracycline Chemotherapy in Triple-Negative Breast Cancer

Background/Aim: The addition of an immune-checkpoint inhibitor (ICI) to chemotherapy improves outcomes in both early-stage and metastatic triple-negative breast cancer (TNBC). However, ICIs are associated with immune-related adverse events (irAEs), such as cardiotoxicity, raising concerns for patients receiving both anthracyclines and ICIs. We sought to determine if combining anthracycline and ICI in TNBC is associated with greater cardiotoxicity than anthracycline alone.